CBLL : 6-month performance

Ticker: CBLL

Wellchange (WCT) : 6-month performance

Wellchange Holdings Co. Ltd. is a holding company, which engages in the provision of enterprise software solution services. It provides tailor-made software solutions, cloud-based software-as-a-service (SaaS) services, and white-labelled software design and development services. 

• Sector: Technology
• Industry: Software - Application
• Full Time Employees: 7
• Founded in 2011 
• Headquartered in Cheung Sha Wan, Hong Kong
• https://www.wchingtech.com

Icon Energy (ICON) : 6-month performance

Icon Energy Corp. engages in the ocean transportation of dry bulk cargoes worldwide. 

Icon Energy is a subsidiary of Atlantis Holding Corp.

• Sector: Industrials
• Industry: Marine Shipping
• Incorporated in 2023 
• Based in Athens, Greece
• https://www.icon-nrg.com

IPO: July 12, 24; 1,250,000 shares at $4.00 per share.

Super Hi (HDL) : 6-month performance

Ticker: HDL

Top Wealth Group Holding (TWG) : 6-month performance

Top Wealth Group Holding Limited provides caviar and caviar-based gourmet products in Hong Kong and internationally. 

• Sector(s): Consumer Defensive
• Industry: Food Distribution
• Full Time Employees: 12
• https://www.imperialcristalcaviar.com

A:  10/7  vol. 1.4 M

B: 10/10  vol. 455

 

 

 

 

Core Scientific (CORZ) : 6-month performance

Core Scientific, which has operations in five U.S. states, mines for bitcoin and other cryptocurrencies.

Sector: Technology

Industry: Software - Infrastructure

Full Time Employees: 325

Founded in 2017 by Darin Feinstein and Mike Levitt

Headquartered in Dover, Delaware

https://corescientific.com

• IPO: 21 July 21 via a merger with a blank-check company Power & Digital Infrastructure Acquisition Corp (XPDI) backed by BlackRock Inc (BLK), in a deal that values the cryptocurrency miner at $4.3 billion.
• 2021: Core was one of the largest publicly traded crypto mining firms in the U.S.
• Filed for bankruptcy in December 2022; relisted January 24, 2024

One month later: Sep 16, 24

Sep 16, 24

Core Scientific’s 104 megawatt Bitcoin mining data center in Marble, North Carolina 

Globavend Holdings (GVH) : 6-month performance

Globavend Holdings Ltd. is an e-commerce logistics provider offering end-to-end logistics solutions in Hong Kong, Australia, and New Zealand. The company's customers are primarily enterprise customers, e-commerce merchants, or operators of e-commerce platforms that offer business-to-consumer (B2C) transactions. It offers a one-stop solution, from pre-carriage parcel drop-off to parcel consolidation, air-freight forwarding, customs clearance, on-carriage parcel transportation, and delivery. 

Globavend serves Hong Kong, as well as four cities in Australia and in New Zealand, and its customers are primarily business-to-consumer e-commerce merchants.

• Sector: Industrials
• Industry: Integrated Freight & Logistics
• Full Time Employees: 7
• Founded by Yau Wai Yiu in 2016 
• Headquartered in Perth, Australia
• https://globavend.com

IPO: November 8, 2023; raised $6 million by offering 1.5 million shares at $4, the low end of the range of $4 to $5. The company offered 0.4 million fewer shares than anticipated.

Vaxxinity (VAXX) : 6-month performance

 

Udemy (UDMY) : 6-month performance

 

Portillo's (PTLO): 6-month performance

 

MiNK Therapeutics (INKT) began trading on the Nasdaq on Fri 15 Oct 21

MiNK Therapeutics, Inc. (NASDAQ:INKT) is a clinical-stage biopharmaceutical company seeking to develop and commercialize off-the-shelf, allogeneic, invariant natural killer T (‘iNKT) cell therapies to treat cancer and other immune-mediated diseases. 

• Sector(s): Healthcare
• Industry: Biotechnology
• Full Time Employees: 33
• HQ: New York, New York
• https://minktherapeutics.com

MiNK Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate includes AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases which is in Phase 1 clinical trials. The company was formerly known as AgenTus Therapeutics, Inc. MiNK Therapeutics, Inc. was incorporated in 2017 and is based in New York, New York.

Technology

iNKT cells are a distinct type of T cells, which in response to lipid antigenic stimulation, rapidly produce within minutes, large amounts of cytokines that can influence other immune cells. These are important immunoregulatory cells though comprising less than 1% of peripheral blood mononuclear cells (‘PBMCs) in the human blood pool. With their durable memory responses and rapid cytolytic features, iNKT cells have been shown to improve microbial and tumor immunity, while suppressing autoimmune disease and promoting tolerance. iNKT cell-derived cytokines and chemokines can modulate several other cell types, including NK cells, conventional CD4+ and CD

Eco Wave Power (WAVE) began trading on the Nasdaq on Thur 1 July 21

Eco Wave Power Global AB, a wave energy company, engages in the development of a wave energy conversion (WEC) technology that converts ocean and sea waves into clean electricity. 

The company was formerly known as EWPG Holding AB (publ) and changed its name to Eco Wave Power Global in June 2021.

• Sector(s): Utilities
• Industry: Utilities—Renewable
• Full Time Employees: 15
• Founded in 2011 
• Headquartered in Stockholm, Sweden
• https://www.ecowavepower.com

Unicycive Therapeutics (UNCY) began trading on the Nasdaq on Tue 13 July 21

 

Molecular Partners AG (MOLN) to collaborate with Novartis (NVS)

 Molecular Partners AG operates as a clinical-stage biopharmaceutical company.

  

• Sector(s): Healthcare
• Industry: Biotechnology
• Full Time Employees: 145
• Founded in 2004 
• HQ in Schlieren, Switzerland
• IPO: 6/16/21
• https://www.molecularpartners.com

Molecular Partners AG to collaborate with Novartis (NVS) to develop DARPin-conjugated radioligand therapeutic candidates for oncology

• Molecular Partners announced a collaboration with Novartis in the form of a license agreement to develop, manufacture and commercialize DARPin-conjugated radioligand therapies. The collaboration will combine Molecular Partners' industry-leading ability to rapidly generate high-affinity DARPins and the RLT capabilities and expertise of Novartis.
• Under the agreement, both parties will collaborate on the discovery and optimization of the therapeutic candidates. Novartis would be responsible for all clinical development and commercialization activities. Novartis will pay $20 million upfront to Molecular Partners, total potential development, regulatory and commercialization milestone payments of up to $560 million, and up to low double-digit percent of royalties.

Privia Health Group (PRVA) reported earnings on Mon 8 Nov 21 (b/o)

Sector(s): Healthcare
Industry: Health Information Services
Full Time Employees: 559
http://www.priviahealth.com
IPO: Thur Apr 29, 21

• Total revenue for the quarter grew ~21.4% YoY to reach $251.5M, with Practice Collections rising ~18.1% YoY to $401.5M.

• However, the company reported a net loss of $9.1M compared to ~$16.7M of net income in the previous year as general and administrative expenses more than trebled to $33.9M.

• “We expect to accelerate top-line growth and continue to expand our profit margin as we execute on our multiple market opportunities in the coming year,” CEO Shawn Morris remarked, noting a ~31.5% YoY increase in care margin and ~51.9% YoY rise in adj. EBITDA.

• For 2021, the company has raised its guidance with newly projected GAAP revenue standing at $900M – $920M, well ahead of $876.8M in the consensus.

Alset EHome (AEI) : 6-month performance

 

Virios Therapeutics (VIRI) began trading on the Nasdaq on Thur 17 Dec 20

• Sector(s): Healthcare
• Industry: Biotechnology
• Full Time Employees: 3
• http://www.virios.com

 

Virios Therapeutics is a development-stage biotechnology company focused on advancing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response, such as fibromyalgia ("FM"). Overactive immune response related to activation of tissue resident Herpes Simplex Virus-1 ("HSV-1") has been postulated to be a potential root cause of chronic illnesses such as FM, irritable bowel disease ("IBS"), chronic fatigue syndrome and functional somatic syndrome, all of which are characterized by a waxing and waning manifestation of disease. While not completely understood, there is general agreement in the medical community that activation of HSV-1 is triggered by some form of environmental and/or health stressor. Our lead development candidate ("IMC-1"), is a novel, proprietary, fixed dose combination of famciclovir and celecoxib. IMC-1 represents a novel combination antiviral therapy designed to synergistically suppress HSV-1 activation and replication, with the end goal of reducing viral mediated disease burden.

Borr Drilling Limited (BORR) began trading on the NYSE on Wed 31 Jul 19

Norwegian drilling contractor Borr Drilling Limited offered 5 million shares in an IPO, with the pricing fixed at $9.30 per share.

The common shares continue to be listed under the ticker "BDRILL" on the Oslo Børs.
Website www.borrdrilling.com
CEO Svend Anton Maier

Lockup Period (days) 180
Lockup Expiration 01/27/2020
Quiet Period Expiration 09/09/2019

The Company
Borr is an international offshore shallow-water drilling contractor providing offshore drilling services to the oil and gas industry. It primarily owns, contracts and operates jack-up rigs for operations in shallow-water areas of depth up to about 400 feet.

The company owns 27 rigs, including 26 jack-up rigs and one semi-submersible rig. With the additional eight jack-up rigs the company is expected to take delivery by the end of 2020, it will have a fleet of 30 jack-up rigs.

Borr currently operates in significant oil producing geographies throughout the world, including the North Sea, the Middle East, Mexico, West Africa and Southeast Asia.

WSG : 6-month performance

Tradeweb Markets (TW) : 6-month performance